本文選題：芪芍膠囊 + 糖尿病腎病　； 參考：《中國(guó)實(shí)驗(yàn)方劑學(xué)雜志》2016年03期

【摘要】：目的:探討芪芍膠囊聯(lián)合厄貝沙坦治療糖尿病腎病(DKD)患者的療效。方法:選取2014年1月至2015年4月期間河北省中醫(yī)院收治的84例DKD患者為研究對(duì)象,并隨機(jī)分為觀察組和對(duì)照組,兩組各42例。對(duì)照組給予厄貝沙坦治療,150 mg qd,觀察組在對(duì)照組治療的基礎(chǔ)上加用芪芍膠囊,5粒tid。比較兩組治療前后的糖代謝指標(biāo)和腎功能指標(biāo),并比較兩組患者的療效。結(jié)果:治療后觀察組的空腹血糖(FPG),糖化血紅蛋白(Hb A1c)均顯著低于對(duì)照組(P0.05),治療后觀察組的血肌酐(SCr),尿蛋白排泄率(UAER),24 h尿蛋白(24 h UP),尿微量白蛋白(m ALB),尿微量白蛋白與肌酐比(m ALB/UCr),血尿素氮(BUN)分別為(135.7±18.9)μmol·L-1,(155.3±28.1)mg·(24 h)-1,(1.53±0.44)g,(39.7±12.9)μg·L-1,(15.5±3.9)mg·g-1,(6.59±0.87)mmol·L-1,均顯著低于對(duì)照組的(163.6±18.0)μmol·L-1,(170.6±32.3)mg·(24 h)-1,(1.79±0.52)g,(47.4±14.4)μg·L-1,(17.7±3.8)mg·g-1,(7.06±0.93)mmol·L-1(P0.05)。觀察組的臨床療效明顯優(yōu)于對(duì)照組(P0.05)。結(jié)論:與單用厄貝沙坦相比,芪芍膠囊聯(lián)合厄貝沙坦治療能更加顯著地改善DKD患者的腎功能,延緩其進(jìn)展,療效顯著,充分顯示了中西醫(yī)治療的獨(dú)特優(yōu)勢(shì),值得臨床推廣應(yīng)用。
[Abstract]:Objective: to investigate the curative effect of Qishao capsule combined with irbesartan on diabetic nephropathy (DKD) patients. Methods: from January 2014 to April 2015, 84 patients with DKD were randomly divided into observation group and control group, 42 cases in each group. The control group was treated with irbesartan 150 mg QD, and the observation group was treated with 5 capsules of Qishao capsule on the basis of the treatment in the control group. The indexes of glucose metabolism and renal function before and after treatment were compared between the two groups. Results: the fasting blood glucose level of observation group was significantly lower than that of control group (P 0.05). After treatment, the levels of serum creatinine, urinary protein excretion rate and urinary protein excretion rate in observation group were significantly lower than those in control group (P < 0.05). The urinary albumin excretion rate and urinary albumin excretion rate were 24 h, 24 h, and 24 h, respectively, respectively. 鐧戒笌鑲岄厫姣，

本文編號(hào)：1906964